Mark Parry

With drug discovery programmes increasingly focused on biological drug substances for both respiratory and systemic targets, the need to develop effective solutions for nasal and inhaled delivery is becoming increasingly vital for the industry. Biologic and DNA based modalities such as oligonucleotides, proteins, antibodies, and a range of other complex forms all present unique problems for developing effective respiratory delivery that challenge some of the accepted approaches and conventions. The talk will address the key principles, challenges, and technologies involved in building effective OINDP products from a range of biologic APIs and will draw examples from real world projects to highlight key parts of the development programmes.